Halozyme Withdraws Evotec Bid

Halozyme gains after withdrawing Evotec bid
Shares of Halozyme Therapeutics (NASDAQ:HALO) added ~12% in the premarket on Friday after the drug delivery technology company withdrew its non-binding proposal to acquire German drugmaker Evotec SE (NASDAQ:EVO).
Halozyme withdraws $2B bid for Evotec after German biotech was 'unwilling to engage'
Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to engage with us to explore a potential combination,” Halozyme president and CEO Helen Torley said in a Nov. 22 release.
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target in sight and an FDA veteran plans retirement.
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a detailed analysis.
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in cash,
Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
Halozyme (HALO) is up 11% to $50.99 in pre-market trading.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks
BRIEF—Halozyme withdraws non-binding offer for Evotec
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash.
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. Most Read from BloombergSaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway Expansion and Emissions“We feel confident in being able to fund this as a fully cash deal,
Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash
Halozyme Therapeutics (HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for EUR 11.00 per share in cash,
Halozyme withdraws $2.1 billion buyout offer for Evotec
Halozyme Therapeutics has withdrawn its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday.
Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal
Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the company withdrew its €2 billion ($2.10 billion) proposal to acquire German drug developer Evotec.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Quest Partners LLC
Quest Partners LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1,386.0% during ...
San Diego Union-Tribune1d
San Diego’s Halozyme withdraws proposed $2.1B acquisition of Evotec
San Diego biotech firm Halozyme Therapeutics is walking back its proposed $2.1 billion acquisition of Evotec, saying the ...
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...
Halozyme’s Transformative Acquisition of Evotec: A Strategic Move for Growth and Market Expansion
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...